ideas42 Channels Unique Behavioral Science Approach to Cybersecurity With Launch of Novella Highlighting Key … – Marketwired (press release)

NEW YORK, NY--(Marketwired - March 20, 2017) - Leading non-profit behavioral design firm ideas42 today unveiled a unique approach to highlighting and resolving key behavioral problems in cybersecurity with the launch of an original, serialized novella.

The new "true-crime"-style short story Deep Thought: A Cybersecurity Story dramatizes the human factors in cybersecurity and is followed by a robust index of key insights from behavioral science that can be used to improve security protocols. The narrative, to be released in multiple installments, highlights the human actions and decisions that often compromise digital information and computer security. These range from password issues to more complex concerns such as coding practices and organizations' resource investment choices.

Despite public and private sector investments in sophisticated security systems, the level of risk is immense. In the search for answers, efforts have been heavily skewed toward finding technological solutions. However, up to 80% of the cost attributed to cyber-attacks is actually a result of human error.

With Internet access rapidly expanding across the globe and the proliferation of greater connectedness across business, finance, and individuals, ensuring privacy and security is more important than ever, as underscored by recent high-profile breaches such as the hacking of American political party systems during the 2016 election cycle.

"It is because of the urgency around strengthening cybersecurity that we chose to present our insights as an engaging novella instead of using the more traditional white paper approach," said ideas42 Executive Director Josh Wright. "With the release of a unique piece like Deep Thought: A Cybersecurity Story and our supporting analysis, we hope to reach more leaders and decision-makers who can take needed steps to increase the strength of their organizations' digital networks."

The first installment of ideas42's novella debuted today at New America's Cybersecurity for a New America conference and can be read at ideas42.org/cyber.

"Simply clicking on a bad link can be devastating to network security, and the strongest security network in the world is only as good as the human with the password," continued Wright, "Furthermore, human error in security is not limited to end-users. The challenges around understanding and addressing human behavioral factors in cybersecurity present a rich vein of opportunity for making the system as a whole more robust."

ideas42's work in cybersecurity is supported by the William and Flora Hewlett Foundation Cyber Initiative in partnership with New America's Cybersecurity Initiative. The goal is to focus on behavioral insights and solutions that can be adopted quickly and brought to scale. For a full copy of the novella and behavioral insight appendix contact us at cyber@ideas42.org. For a video introducing the novella, click here.

About ideas42

ideas42 has a clear mission: to use our unique experience at the forefront of behavioral science to change millions of lives. We create innovative solutions to tough problems in economic mobility, health, education, consumer finance, energy efficiency and international development. Our approach is based on a deep understanding of human behavior and why people make the decisions they do. Working closely with our partners from government, foundations, NGOs and companies, we have more than 80 active projects in the United States and around the world.

Embedded Video Available: https://youtu.be/GkU5UIpw9IE

More here:
ideas42 Channels Unique Behavioral Science Approach to Cybersecurity With Launch of Novella Highlighting Key ... - Marketwired (press release)

Chemistry Seminar – Dr. Christopher Jones – Seton Hall University News & Events

Tuesday, March 21, 2017

By Nicholas Snow

The Department of Chemistry and Biochemistry Rose Mercadante Seminar Series is pleased to present a seminar entitled "Amine-Modified Silicates as Acid/Base Bifunctional Catalysts and Catalyst Supports" by Dr. Christopher Jones of the School of Chemical & Biomolecular Engineering, School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA.

The seminar will be held at 5:45 p.m. on Tuesday March 28, 2017 in the Helen Lerner Amphitheater, Science and Technology Center. The University Community is invited to attend.

Amine modified porous silicates are highly versatile materials. We have explored synthesis-structure-property relationships for these materials in the separation of organic species from gas or liquid phases, as well as for CO2 capture. Building on this, our recent endeavors in the design and application of porous silicate supported amines in catalysis will be described. Catalysts based on discrete molecular amines that act as basic sites have been employed in reactions of importance in synthetic organic chemistry such as aldol condensations and related reactions. Similar materials are demonstrated to be useful supports for metal nanoparticles that offer outstanding performance in the semi-hydrogenation of alkynes into cis-alkenes.

Professor Jones is the Love Family Professor of Chemical & Biomolecular Engineering and the Associate Vice President for Research at Georgia Tech.

Dr. Jones leads a research group that works in the broad areas of materials, catalysis and adsorption.

Since joining Georgia Tech, Dr. Jones has been recognized with a number of awards for his research and teaching. The American Chemical Society recognized his catalysis research with the Ipatieff Prize in 2010, followed by the North American Catalysis Society with the Paul H. Emmett Award in Fundamental Catalysis in 2013.

In 2016, he was recognized by the American Institute of Chemical Engineers as the top chemical engineer under 45 with the Andreas Acrivos Award for Professional Progress.

Dr. Jones is the founding Editor-in-Chief of the new journal, ACS Catalysis, which was recognized with the 2012 Prose Award as the Best New Journal in Science, Technology or Medicine, by the American Association of Publishers.

As Associate Vice-President for Research, Jones is responsible for leading and managing interdisciplinary research activities across six colleges, the Georgia Tech Research Institute, and the Enterprise Innovation Institute.

Categories: Arts and Culture , Health and Medicine , Research

For more information, please contact:

Read the original here:
Chemistry Seminar - Dr. Christopher Jones - Seton Hall University News & Events

Biodiversity, Biotechnology and Intellectual Property: their relevance for the development of Colombia – Lexology (registration)

Biotechnology has emerged as one of the most forward-looking fields of science in recent decades, and a large number of nations have set their sights on it as a long-term development pillar, given its wide range of applications and the leapfrogging of current information technology, which allows to further exploit its potential.

Biotechnology has already proven to be an option for growth in multiple economic sectors, finding applications of high importance in sectors such as pharmaceuticals, food, veterinary, cosmetic, environmental, agricultural, energy, among others, which make it an opportunity for those developing countries in search of a boost for the progress of their economies.

It is then in biotechnology that a country like Colombia, which occupies the second place after Brazil in world biodiversity, with around 10% of the fauna and flora of the planet, can find possibilities of great impact for its economic growth and technological development. However, it is not a simple challenge if one takes into account the little investment that, unfortunately, is destined for R&D in the country. For example, according to World Bank data for the year 2014, Colombia allocated about 0.2% of GDP for this purpose, an amount significantly lower than the world average of about 2%, and much lower than the number one country in this regard, South Korea, which investment in R&D is above 4% of GDP.

In this manner, the government, academics and companies must work together to transform this enormous biodiversity into a factory of knowledge and innovation that translates into solutions to both local and global problems, which in the long term will allow to narrow the economic-technological gap between Colombia and the most developed countries in the world.

Thus, in the commitment to research in general as a driving force for development, and in particular concerning the emerging biotechnology, intellectual property plays a decisive role for its progress; this is due to the fact that tools for the protection of inventions, such as patents, greatly influence the decision of companies to invest or not their capital in a particular sector, and even more in biotechnology, which is undoubtedly one of those with highest cost in both R&D and product development and process design.

Hence, it is possible to evidence in different countries a closely related upward trend between R&D spending and the filing of patent applications, making them a clear indicator of a country's innovation and inventive step. By way of example, this is clearly visible when comparing the number of patent applications filed in Colombia and South Korea, using data provided by the World Bank in this regard for the same year mentioned above. In Colombia, in 2014, 260 patent applications were filed by residents and 1898 by non-residents; values much lower than those in South Korea where the numbers amount to 164073 patent applications filed by residents and 46219 by non-residents for the same year.

Therefore, it is necessary a vision change from the government of Colombia that promotes the injection of public and private capital in R&D, which is supported by an intellectual property system that provides adequate legal protection to the inventions and compensates the economic efforts made in innovation. Taking into account the characteristics of the country, Colombia has the potential to establish, as one of the pillars of its economy, its own biodiversity together with biotechnology; however, to this day, this latter is greatly underestimated.

In this sense, the challenge for Colombia in the coming years is to recognize and take advantage of the immense potential for scientific research that it possesses, especially in terms of biotechnology, in order to have in the future the ability to offer products and services with high standards of quality and added value, derived from a sustainable exploitation of its natural resources that goes hand in hand with policies ensuring the technical, legal and economic conditions conducive to its realization.

See more here:
Biodiversity, Biotechnology and Intellectual Property: their relevance for the development of Colombia - Lexology (registration)

Assessing biotechnology in the age of cloud computing – Cloud Tech

In order to ensure that patient outcomes are constantly being improved upon it is important that the speed of change within the biotechnology sector occurs at an exponential rate. However, this continued drive for innovation puts immense pressure on IT departments to develop new technologies at speed, while also making sure that they do this cost effectively.

Add to this the fact that, more so than other industries, biotech firms are extremely tightly regulated. As a result, IT groups within this industry are often reluctant to introduce more complexity into what is already a very complex environment. To them, expanding a data centre can often feel a whole lot easier than navigating the regulations of the cloud. Despite this, growth in the demand for cloud computing in life sciences research and development is escalating due to the benefits it brings to the industry benefits like exceeding regulatory requirements, for example.

At iland, we have worked with many companies in the healthcare, life sciences and biotech industries. Therefore, we know from experience that the implementation of cloud computing in biotechnology empowers organisations with the control and flexibility needed to lead the way in both the research world as well as the businesses world. For example, we recently worked with a US based biotechnology organisation on their backup and disaster recovery (DR) strategy, and were able to drive global data centre consolidation with host-based replication to the iland cloud. As a result, their DR testing and auditing processes were greatly simplified and streamlined which drove significant cost savings as well as compliance assurance.

If you still need convincing here are three key benefits that we believe cloud brings to biotech organisations:

When the Human Genome Project began it was one of the most extensive research projects in the field to date costing billions of pounds and lasting over a decade. These days, thanks largely to cloud technology, it can bedone in just 26 hours. Things such as drug R&D, clinical research as well as a whole host of other areas have benefited just as much from the rapid growth of computational power. The better your technology is at crunching huge sets of data, the quicker you can innovate.

Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning. Labs can also benefit from immense computing power without the cost and complexity of running big onsite server rooms. They can also scale up at will in order to make use of new research and ideas almost instantly.

Concerns have been voiced that so called scientific computing in the cloud may make results less reproducible. One concern is that cloud computing will be a computing 'black box' that obscures details needed to accurately interpret the results of computational analyses. In actual fact, by leveraging the application program interfaces (APIs) in the iland cloud, biotech customers are able to integrate cloud data back into on-premises IT systems to ensure that data analyses done in the cloud can be easily shared and consumed by other applications. Essentially, cloud computing services bring more players to the table to solve the giant puzzle. Its a win-win situation from an economic and patient standpoint, and several big name companies are jumping on the biotech cloud bandwagon.

Biotech companies need to maintain strong access and authentication controls, while also being able to collaborate easily.For this reason audit trails and other measures are often required to verify that information has not been improperly altered, and that good experimental and manufacturing procedures have been followed. At the same time biotechnologists need to be able to access and share data across multiple departments or even multiple companies.

Cloud computing in biotechnology makes this all possible. Theiland cloud, for instance, centralises data, ensuring security and data sovereignty while facilitating collaboration. It supports extensive user and role based access control, two-factor authentication and integrity monitoring to prevent improper access and changes. In addition to data encryption, vulnerability scanning and intrusion detection, these measures facilitate security and compliance, without disrupting the internal workflow.

Complex regulatory requirements and logistics combined with niche markets make efficiency paramount within biotechnology. Even minor mistakes as a result of sloppy process management can easily result in major issues. Real-time operational reporting dramatically improves efficiency, quality control and decision making, allowing organisations to react instantly to challenges and opportunities, both internal and external.

As well as enhanced billing visibility and resource management functions, the release of our latest Secure Cloud Services means that the iland cloud now includes on-demand security and compliance reports. This advanced cloud management functionality is designed to foster strategic, self-sufficient control of a cloud environment, optimising overall cloud usage and costs to drive business initiatives and growth.

Without a shadow of a doubt, cloud technology can help biotechnology companies build the future.From research and development to marketing, computing affects everything your organisation does. With rich experience in the biotech, healthcare and life sciences sector, you should talk to iland today to find out how our cloud hosting services can give you the power to develop at the speed of thought, not the speed of compliance or processing.

Read more: Why the cloud could hold the cure to diseases

Read the original:
Assessing biotechnology in the age of cloud computing - Cloud Tech

How Many More Seasons Does Grey’s Anatomy Have Left In It? Ellen Pompeo Says… – E! Online

When Grey's Anatomy returns for its already-ordered 14th season this fall, it will not only air its 300th (!!) episode, but it'll finally tie classic sitcom The Adventures of Ozzie and Harriet for ABC's longest-running series ever. (And unlike that other show, Shonda Rhimes and Co. show no signs of slowing down!) In this day and age of Peak TV, for any series to even come close to a milestone like this is a damn near miracleand the cast knows it.

"It's been perfect to be able to have a job that you can go to," OG Grey's cast member Justin Chambers told E! News on the red carpet at the PaleyFest event honoring the series. "Just having a routine and working with people that you love and enjoying your character. To be able to say that you've been on a show this longit's a great gig to be able to say that."

Chandra Wilson, who's been there since day one alongside Chambers, couldn't help but agree. "I'll tell you, as an actor, the opportunity to be involved in something historic is amazing, so I love that," she gushed. "These characters and this show are cemented in history, so to know that little contribution is thereand it will always bethat's amazing. So it's a great honor."

Kevin McKidd, who joined the series five years into its run, couldn't be more thankful for getting the opportunity to be a part of Grey's Anatomy. "I pinch myself every single day that I'm part of it," he admitted. "It's unbelievable. I really feel honored and deeply grateful that I'm part of a thing that's actually making a piece of history. It's a really exciting thing and not to be taken lightly. These things don't happen often."

So, how much longer do Ellen Pompeo and her co-stars think they have left in them? Do they dare dream of giving Gunsmoke's record 20 seasons a run for their money in order to become TV's longest running live-action series ever?

"I don't know. I know that we want to try to," the leading lady herself admitted before stopping herself short. "Well, let's just see, you know? I don't like to take things for granted. You can't just assume the show can go on forever. It's up to the fans. And the fans will let us know how long they want the show to air."

In that case, she may want to settle in for the long haul, because if it's up to the fans, Grey's Anatomy isn't going anywhere anytime soon.

For more from Pompeo and her co-stars, be sure to check out the videos above.

Grey's Anatomy airs Thursdays at 8 p.m. on ABC.

Read more:
How Many More Seasons Does Grey's Anatomy Have Left In It? Ellen Pompeo Says... - E! Online

Study: Parenthood can boost your longevity – Detroit Free Press – Detroit Free Press

Ana Veciana-Suarez, Miami Herald (TNS) 11:08 p.m. ET March 18, 2017

Spinning might look about the same as outdoor cycling or riding a stationary bike, but in many ways, it's a far more intense workoutand one of the easiest to overdo. Time

1 of 10

A recent Danish study has just given us more reason to pause before reaching for the pain killers. Angeli Kakade (@angelikakade) has the story. Buzz60

2 of 10

Bad news: experts say using toilet seat covers won't stop germs, and using toilet paper as a seat cover is actually worse! Find out why. USA TODAY

3 of 10

Jet lag got you feeling down? Youre not alone. Angeli Kakade (@angelikakade) has the story. Buzz60

4 of 10

Did you know not properly taking care of your teeth can affect other parts of your body too? Maria Mercedes Galuppo (@mariamgaluppo) has more. Buzz60

5 of 10

Kevin Breen suffered from a rare case of strep throat. Veuer's Emily Drooby (@emilydrooby) has the story. Buzz60

6 of 10

Optimize your health by eating during these times. Buzz60's Emily Drooby (@emilydrooby) has the story. Buzz60

7 of 10

For the second year in a row, Naples, Fla. and its surrounding area take the top spot as healthiest and happiest in America as part of the Gallup-Healthways 2016 Community Well-Being Rankings. Buzz60

8 of 10

A new study links bacon and other foods we love to many U.S. deaths. Researchers also found the same link for not eating enough healthy foods. Sean Dowling (@seandowlingtv) has more. Buzz60

9 of 10

Americans love their cheese. Angeli Kakade (@angelikakade) has the story. Buzz60

10 of 10

Why you should rethink your spinning obsession

The Danish have linked Ibuprofen to cardiac arrest

Ew! Research finds toilet seat covers do not stop germs

Is your sleep schedule making you sick?

Side effects of not brushing enough go way beyond your pearly whites

Strep throat leads to quadruple amputation for one man

Is late-night snacking affecting your health?

What's the happiest and healthiest city in America?

The foods you love might kill you

Is cheddar cheese as addictive as heroin?

A study out of Sweden says parenting can extend your life.(Photo: David Sacks/Getty Images)

Want to live longer? Have children.

If you don't die early from child-rearing stress, parenthood will boost your longevity chances, according to a new study out of Sweden.

Researchers at the Karolinska Institute used national registry data to track 1.5 million Swedes born between 1911 and 1925 as they lived through their last years.

While the risk of death naturally increased with age for all adults, the team found that those with children had greater longevity.

"Support from adult children to aging parents may be of importance for parental health and longevity," researchers write. "At old age, the stress of parenthood is likely to be lower and instead, parents can benefit from social support from their children. In addition, parents have on average more healthful behaviors than childless individuals."

The study, published in the Journal of Epidemiology and Community Health, also revealed that having children is actually more beneficial as you age, and it is particularly greater for men than women.

Men who were not married but had children were also living longer than those with a spouse. For example, 60-year-old men who had children had about two years more of life than those without, with a life expectancy of 20.2 and 18.4 years respectively.

Bag of toys in a bathtub(Photo: Creatas Images via Getty Images)

For women at 60, those with children had life expectancies of 24.6 years while those without children had 23.1.

The life expectancy difference continued as the study group grew older. By 80, parents had a life expectancy of 7.7 years for men and 9.5 years for women. In comparison, the 80-year-olds without children had a life expectancy of 7 years for men without children and 8.9 years for women without children.

Read more:

Michigan couple hopes perky music video will help them adopt

Boy born without limbs in line for MSU-designed prosthetic

The sex of the child had no influence on their parent's longevity, according to researchers, but it should be noted that this finding was based only on families with one child.

"Perhaps being the only child is related to a greater responsibility of parents, reducing the difference in the amount of help given by sons and daughters," they study authors write.

Of course parenthood isn't the only thing boosting longevity.

"In terms of all other causes that would affect your death risk in these old ages, having a child is not among the greatest ones," study co-author Karin Modig told The Guardian. "But it is still a 1.5 percent difference [for 90-year-old men] which is still substantial."

Read or Share this story: http://on.freep.com/2n9QXji

Link:
Study: Parenthood can boost your longevity - Detroit Free Press - Detroit Free Press

A revolutionary genetic experiment is coming to rural Burkina Faso – PRI

This story was originally published on STAT.

BANA, Burkina Faso This small village of mud-brick homes in West Africa might seem the least likely place for an experiment at the frontier of biology.

Yet scientists here are engaged in what could be the most promising, and perhaps one of the most frightening, biological experiments of our time. They are preparing for the possible release of swarms of mosquitoes that, until now, have been locked away in a research lab behind doublemetal doors and guarded 24/7.

The goal: to nearly eradicate the population of one species of mosquito, and with it, the heavy burdenof malaria across Africa.

These scientists are planning to release mosquitoes equipped with gene drives, a technology that overrides natures genetic rules to give every baby mosquito a certain trait that normally only half would acquire. Once such an insect gets out into the wild, it will move indiscriminately and spread its modified trait without respect for political borders.

No living thing no mammal, insect, or plant with a gene drive has ever been set free. But if all goes as planned, it mighthappen here, in a remote village of about a thousand people, where the residents dont even have a word for gene.

Despite such barriers, this is in some ways the most logical place to carry out the experiment. Nowhere does malaria exact a higher toll than here in sub-Saharan Africa, where hundreds of thousands die from the disease every year. And Burkina Faso already houses one of Africashighest-profile malaria research laboratories.

It may be six years before the gene drive mosquitoes are actually released in Burkina Faso, but scientists are already working around the clock to prepare the community for their release. Researchers in Mali and Uganda are also working toward the same goal under the banner of the Target Malaria project, propelled by $70 million from the Bill and Melinda Gates Foundation and support from research laboratories in England and Italy.

Speaking through interpreters, residents across Burkina Faso told STAT that they are grateful for the scientists work, and are eagerly looking forward to eliminating the dreaded disease.

But scientists still face achallenge: making sure that people understand and accept thenewfangled genetic technology behind it all. That means building trust and doing basic education explaining not only the impact of genetically engineered insects arriving in their homes, but also what genetics is in the first place.

*****

Driving west from Bobo-Dioulasso, the sleepy regional capital that is Burkina Fasos second-largest city, the pavement fades away into an undulating dirt path. Traffic dissolves into a trickle of motorbikes whose drivers wear surgical-style masks to protect them from the dust. Donkey carts plod along under the weight of flattened grass, outpacing camels weighed down by saddlebags.

At the height of the dry season in late December, eight scientists and social scientists pulled off the dirt road,carrying a box of a hundred adult mosquitoes and a 1-liter bottle filled with wriggling larvae.

For the past few years, the scientists from the Institut de Recherche en Sciences de la Sante (IRSS) in Bobo-Dioulasso, where the countrys Target Malaria team is based,have been teaching Bana residents basic mosquito facts, including that the bugs transmit malaria. Many in Burkina Faso believe that malaria can be spread by eating too many greasy or sweet foods, said Lea Pare, the anthropologist who is leading a national effort to engage local citizens in Target Malaria.

Beyond live mosquitoes, the team also uses pictures to help explain the complicated scientific information: a set of thirteen cards, laminated like giant placemats, which detail the different phases of the project. In Bana, they talk through the first four of these cards, which show gigantic female mosquitoes biting humans, with small red squiggles flowing through the proboscis and into the persons body. On the fourth card, a scientist wearing a white coat is looking at those mosquitoes under a microscope.

White coats are very familiar to residents of Bana. For the last three years, a team of researchers has lived part-time in the village, sleeping in an old cement house retrofitted into a scientific base camp. These technicians, with the help of local volunteers, count the number of mosquitoes in the homes, observe the mating swarms at dusk, and dust mosquitoes with colored powder to track where they travel around the village.

They are gathering data on the mosquito population to feed into intricate computer models that will help them determine how the gene drive mosquitoes should be released.

When the technicians stepped into one home on a recent day, they laid thick sheets across the floor of a bedroom and filled it with acrid-smelling insecticide spray. After 10 minutes, they hauled the sheets out, opened them up, and crouched over a small pile of dirt specks: only one male mosquito.

For low mosquito season, it wasnt surprising. During the rainy season, however, which starts in June, there might be a few hundred mosquitoes in each room, said technician Ibrahim Diabate.

Men living in the treated homes were excited, even jubilant, that the researchers were working in the village. They understood that the scientists had a longer-term plan to battle the mosquitoes, but they were also happy for the insecticide spray in the present moment.

Since you started this work, praise God, malaria has been reduced, because mosquitoes dont bite us anymore, said Ali Ouattara, one elder in the community.

In the next phase of the project, scientists will have to explain to Ouattara why theyre actually releasing more mosquitoes.

Going straight from zero to gene drives would be too extreme, so scientists are planning to release regular genetically engineered mosquitoes first either here in Bana or in one of two other villages nearby.

Those mosquitoes, which could be released next year, are sterile males: Most of them are male, and they cannot have offspring. A field release is not intended to reduce the prevalence of malaria; rather, it is to prepare the scientists and the locals for the eventual arrival of the gene drive mosquitoes, said Delphine Thizy, who directs the work of engaging local, national, and international leaders for the project.

The outreach teams have started talking about DNA with their flash cards. But they arent saying anything yet to the locals about the much more powerful, and complicated, idea of a gene drive.

Partly thats because researchers didnt want the residents of Burkina Faso to expect that a miracle solution to the malaria epidemic isjust around the corner, Thizy said. Scientists in London havent yet created the gene drive mosquitoes that would be used, and field trials of such mosquitoes are years away.

Also, she said, gene drives are hard to understand.

To be fair, even in Europe and in North America, its complex to understand gene drives in one shot.

If gene drive mosquitoes arrive in Burkina Faso, it will be thanks to the vision of Abdoulaye Diabate, a soft-spoken medical entomologist with a singular mission: to stop malaria.

The disease is ever-present in thiscountry mosquito nets hang for sale by the roadside, and hotel proprietors lay out smoldering coils in the courtyards to ward off mosquitoes as dusk falls.

Diabate, who is deeply involved in malaria eradication efforts worldwide, became dismayed when, in the 1990s, he realized that mosquitoes were building up resistance against the insecticide used on bed nets here.

If this is the only tool we have in hand, then forget about malaria elimination, Diabate said.

But,in 2012, he received an invitation to a meeting about the Target Malaria project, which was focused on solutions involving genetic engineering. He jumped at the chance.

Today he is leading the Burkina Faso team, trying to get the whole world from remote villages to international diplomats on board with his ambitious research.

Meanwhile, thousands of miles away in the United Kingdom, geneticists at Imperial College London are working on designing the gene drive mosquitoes. Specifically, theyre studying two different ways to disrupt the reproductive system of one particular species, Anopheles gambiae: reduce the number of female babies (only females bite and spread the disease) or stop the mosquitoes from having offspring in general.

To make the population predominantly male, Austin Burt, Target Malarias primary investigator, and collaborators are studying an X shredder a gene that destroys the X chromosome in sperm, making all offspring males. Alongside that, theyre looking at reducing the number of mosquitoes of both sexes by creating genes that make them sterile.

Either approach might lead to massive population collapse within two to eight years, according to Charles Godfray, a University of Oxford professor and biologist who works on modeling for the Target Malaria project.

But the insects wouldnt go extinct, scientists say. The gene drive mosquitoes currently under consideration would only reduce the population of Anopheles gambiae enough to stop the transmission of malaria.

The foundation is not interested in eliminating Anopheles mosquitoes, said Dr. Scott Miller, who leads malaria research and development for the Gates Foundation. Were interested in eliminating malaria.

It will take years to reach the point that scientists will be ready to test the gene drive mosquitoes in the wild. In the meantime, they are facing the challenge of winning over local residents who might be wary of these new creatures.

Mariam Pare was initially frightened. A commanding woman who teaches in a Koranic school, Pare livesacross the street from the IRSS in Bobo-Dioulasso. Shesaid that when she first heard about mosquito research going on at the lab, she feared that the scientists were breeding mosquitoes to let loose on the locals. But after meetings and discussions with project staff, she came to understand that theyare instead trying to fight against the mosquito.

She even took a tour of the insectary that currently holds the gene-edited sterile male mosquitoes, and could eventually hold the gene drive ones. She saw fans that would suck away mosquitoes if they happened to escape from their cages, and a hot water bath where unnecessary mosquitoes go to die.

Because I saw what was going on in there, I believe and trust the people that work in there, she said.

Earning Pares trust was particularly important for the team because she lives so close to the insectary, her consent was required to import the sterile male mosquitoes. That requirement isnt a legal one, but one that the Target Malaria project has put in place. The Gates Foundation has also said that gene drive mosquitoes will only be released if the host country agrees.

Lassina Diarra, a tailor whose turquoise-walled shop is down the road from the research lab, also had to give his consent. Sitting on the corner of a table among scraps of fabric and hand-tailored suits, he said that he was impressed by the scientists transparency and reliability. Two outreach workers recruited him to serve on a group of 12 local leaders who communicateinformation about the project to the citys residents, dubbed the relay group, along with a different committee to address community grievances. Every few weeks, he knocks on doors up and down the streets, updating his neighbors on the scientists progress.

In June, Diarra and Pare both signed off on the arrival of the sterile males. So did Kadidia Ouattara, one of the relay group members and the president of multiple neighborhood associations. She recalled a joyous gathering filled with dance and song.

Ni fonyon douma ni bora mi? they sang in Dioula. Ni fonyon douma ni bora mi?

The song translates to, Where did this good air come from? and, more colloquially, means, This is too good to be true!

Ouattara said that it is a traditional song commemorating good news a wedding, the birth of a baby, the success of a student in her exams. And on that day, it was celebrating the impending arrival of genetically modified mosquitoes.

Burkina Faso has experience with genetically modified organisms. One of the first associations some residents make with genetic engineering is Monsanto, which has been selling genetically modified cotton seeds to Burkinabe farmers since the 2000s. But the countrys growers association stopped buying the seeds in 2016 in the wake of concerns about the cottons quality and country-wide protests against the company.

One resident of Bobo-Dioulasso complained that genetically modified food rots quickly, and said that he hopes the mosquitoes suffer the same fate: an early death.

The fight against malaria is a big concern, but the solutions are sometimes scary, said Sylvestre Tiemtore, the director of an organization that represents over half of the nongovernmental organizations in Burkina Faso. The group met with Target Malaria in July, a discussion which was very heated, he said.

In movies he cited Jurassic Park weve seen some research that went out of control, he said.

The mouthparts of a female Anopheles gambiae mosquito. (Jim Gathany/CDC)

Scientists familiar withthe effort here say defining the idea of genetically modified to residents here might be of limited use, because it wont help people understand what the mosquitoes are or what they will really do, said Javier Lezaun, deputy director of the Institute for Science, Innovation, and Society at the University of Oxford, who is not involved in the Target Malaria project. In fact, the phrase might just serve to distract and scare he spoke of another community in Tanzania who thought that a swarm of mosquitoes that invaded a hospital were genetically modified (they werent), and of others in Brazil who thought that Zika arrived as a result of genetically modified mosquitoes (it didnt).

As long as you explain something about the specific capabilities of the mosquitoes, or the limitations of these particular mosquitoes and how theyre supposed to behave in the wild or in the facilities, I think that serves the purpose of explaining genetic modification, Lezaun said.

And thats what many people are curious about. At the July meeting with NGOs, hosted by the Secrtariat Permanent des Organisations Non Gouvernementales (SPONG for short), attendees wanted to know: What would happen to the local ecosystem? And might these engineered mosquitoes be able to transmit other diseases?

Some of these questions dont yethave answers, but others do. A risk assessment commissionedby the Foundation for the National Institutes of Health, a US nonprofit that supports the federal agency, found that the risk of the sterile mosquitoes currently in Bobo-Dioulasso transmitting other diseases was incredibly low; the modified mosquitoes probably wont spread more malaria than their wild cousins; and the genetic modification probably wont spread from the mosquito to other animals.

Outside scientists, convened by the FNIH in May, had previously concluded that Anopheles gambiae is not a keystone species, meaning that if its population shrank dramatically, the ecosystem would not be substantially impacted.

But the meetings continue. Tiemtore, SPONGs director, said that he would like to have a meeting with representatives of different health-related NGOs that are based in Burkina Fasos 13 different regions, to educate them about the project. But that requires money to bring them to the capital, and to cover the costs of the meeting itself.

They might need to rent a room, Tiemtore said. They might need to offer some coffee breaks. That costs money. Who pays for that? If you dont do all of those things, your mosquitoes are going to come out, but they wont be released in the regions, because the people will not agree with it, because they didnt have enough information on it, and they will have the right to be afraid.

The development of powerful new genetic engineering technologies, often outstripping regulators ability to keep up, is forcing scientists to reckon with the ethics of their work in a new way.

Of course, humans have been making potentially irreversible changes to our environment for a long time: clearing forests for farming, building power plants that change the composition of the atmosphere, and producing untold tons of synthetic materials like plastic that will stay in the environment for hundreds of years.

But gene drives lend these questions a different sort of urgency. The genetic technology can quickly change the properties of an entire population of a species, undoing millennia of evolution in a handful of years. And once you let them out of the cage, theres no going back other world-altering technologies have not been self-perpetuating like gene drive animals would be.

So scientists are treading carefully and doing what they can to keep the rest of the world involved. This has led to difficult questions: Who needs to give them permission to do certain things? What does it mean for residents to be fully informed? In answering them, there arent a lot of models to follow. There are only a fewgene drive projects underway in the world, and none has yet resulted in the release of the animalsinto the wild.

Academic research on how to effectively include non-scientists in global healthdecisions is also lacking, said Jim Lavery, an Emory University professor of global health and ethics who has worked with the Target Malaria project in the past.

Right now, Lavery said, scientists can count the number of phone calls they make and the number of people who show up at community meetings, but we dont even have an understanding at a proxy level of what those things are supposed to represent in terms of effectiveness of engagement.

While researchers like Lavery are trying to determine how to measure success, research is plowing ahead. Some scientists are thinking about releasing gene drive mice halfway across the world, in New Zealand, to eliminate invasive species. AndKevin Esvelt, a gene drive guru based at the Massachusetts Institute of Technology, is flying to Argentina in September to talk about using gene drives to get rid of flesh-eating flies.

He has said that gene drives are more important as a societal tool to change the way that science is done it should be open to and inclusive of the people it will impact. To that extent, he praised Target Malarias community work. I honestly dont see how you could do it any other way, he said, citing the language and cultural barriers that the project is working to overcome.

How the project is going to introduce gene drive mosquitoes, though, is an open question. National regulators and international organizations like the World Health Organization are still working on developing guidelines for introducinggenedrive animals.

And in Burkina Faso, Thizy said she hasnt even yet put a lot of thought into what it will mean for local leaders to understand a release of gene drive mosquitoes. She said it will probably include knowing that the modified mosquitoes will stay in the environment and grow in number, until some point at which the population of Anopheles gambiae will be reduced.

But, said Thizy, exactly how the gene drive works may matter less to the people than the impact it will have on them and their lives.

She pointed, by way of analogy, to her previous work as a consultant for a mining company in the Ivory Coast: It wasnt how big is the hole, how many holes, and how does the machine work that the area residents were worried about, she said, but rather how they would be compensated and what jobs would be created.

On a dusty Wednesday morning earlier this year, Kadidia Ouattara arrived at an outdoor market, eager to chat with the vendors about genetically engineered mosquitoes.

As a woman spooned tomato sauce from a gigantic aluminum can onto plastic sheets for individual sale, Ouattara told her about the insect lab just a few minutes walk down the street.

The researchers who work there are trying to reduce the population of mosquitoes, she said. Dont be afraid I saw the inside of the lab and all of the research. There are public meetings where they explain what they are doing, and if there is another one, I will let everybody know.

The woman was delighted. May God help the project be a success, she said.

Farther along, she came upon a butcher who she knew to be particularly recalcitrant. He thinks were getting money from the white people, Ouattara said. But thats not true shes a volunteer.

Ouattara walked up to the man, who was hacking at a piece of meat with a foot-long knife, bits of gristle flying everywhere and flies swarming. Rivulets of blood ran along the dusty ground.

If there is a meeting about the project, I am begging you to come, she said.

Scarcely taking his eyes off of the meat, the butcher mumbled some kind of assent.

Ouattaras enthusiasm was undimmed; she strode off to a woman selling onions. And shed be back soon with more news to share.

Eric Boodman and Kate Sheridan contributed reporting.

Special thanks to Housmane Sereme and Steve Sanou for translation services.

Follow this link:
A revolutionary genetic experiment is coming to rural Burkina Faso - PRI

Scientists find possible Achilles heel of treatment-resistant cancers – Medical Xpress

March 20, 2017 This image shows treatment-resistant chronic myeloid leukemia cells (CML) in laboratory mouse models. Researchers report March 20 in Nature Medicine that two signaling proteins in certain cancer cells make them resistant to chemotherapy treatment. Inhibiting these proteins combined with chemotherapy eradicated CML- and residual disease cells that can refuel the disease -- in laboratory models of leukemia. Credit: Cincinnati Children's

Scientists identify two signaling proteins in cancer cells that make them resistant to chemotherapy, and show that blocking the proteins along with chemotherapy eliminate human leukemia in mouse models.

Reporting results March 20 in Nature Medicine, researchers at Cincinnati Children's Hospital Medical Center suggest that blocking the signaling proteins c-Fos and Dusp1 as part of combination therapy might cure several types of kinase-driven, treatment-resistant leukemia and solid tumor cancers.

These include acute myeloid leukemia (AML) fueled by the gene FLT3, lung cancers fueled by genes EGFR and PDGFR, HER2-driven breast cancers, and BCR-ABL-fueled chronic myeloid leukemia (CML), according to Mohammad Azam, PhD, lead investigator and a member of the Division of Experimental Hematology and Cancer Biology.

"We think that within the next five years our data will change the way people think about cancer development and targeted therapy," Azam says. "This study identifies a potential Achilles heel of kinase-driven cancers and what we propose is intended to be curative, not just treatment."

The weak spot is a common point of passage in cells (a signaling node) that appears to be required to generate cancer cells in both leukemia and solid tumors. The node is formed by the signaling proteins c-Fos and Dusp1, according to study authors. The researchers identified c-Fos and Dusp1 by conducting global gene expression analysis of mouse leukemia cells and human chronic myeloid leukemia (CML) cells donated by patients.

CML is a blood cancer driven by an enzyme called tyrosine kinase, which is formed by the fusion gene BCR-ABL. This fusion gene is the product of translocated chromosomes involving genes BCR (chromosome 22) and ABL (chromosome 9). Analysis of human CML cells revealed extremely high levels of c-FOS and DUSP1 in BCR-ABL-positive chemotherapy resistant cells.

Cancer sleeper cells

Cancer cells often become addicted to the mutated gene that causes them, such as BCR-ABL in kinase-driven chronic myeloid leukemia. Most chemotherapies work by blocking molecular pathways affected by the gene to shut down the disease process. In the case of CML, a chemotherapy called imatinib is used to block tyrosine kinase, which initially stops the disease. Unfortunately the therapeutic benefit is temporary and the leukemia comes back.

Azam and colleagues show in their CML models that signaling from tyrosine kinase - and growth factor proteins that support cell expansion (like interleukins IL3, IL6, etc.) - converge to dramatically elevate c-Fos and Dusp1 levels in the cancer cells.

Working together these molecules maintain the survival of cancer stem cells and minimal residual disease. The dormant cells wait around under the radar screen to rekindle the disease by acquiring additional genetic mutations after initially effective chemotherapy.

Azam says Dusp1 and c-Fos support the survival of cancer stem cells by increasing the toxic threshold needed to kill them. This means conventional imatinib chemotherapy will not eliminate the residual disease stem cells. Doctors can't just increase the dose of chemotherapy because it doesn't target the Dusp1 and c-Fos proteins that regulate toxic threshold.

Targeting c-Fos and Dusp1

After identifying c-Fos and Dusp1, the authors tested different treatment combinations on mouse models of CML, human CML cells, and mice transplanted with human leukemia cells. They also tested treatments on B-cell acute lymphoblastic leukemia (B-ALL).

The treatment combinations included: 1) solo therapy with just the tyrosine kinase inhibitor, imatinib; 2) solo treatment with just inhibitors of c-Fos and Dusp1; 3) treatment with all three combined - imatinib along with molecular inhibitors of c-Fos and Dusp1.

As suspected, treatment with imatinib alone initially stopped CML progression but the leukemia relapsed with the continued presence of residual disease cells. Treatment with c-Fos and Dusp1 inhibitors alone significantly slowed CML progression and prolonged survival in a majority of mice but wasn't curative. Treatment for one month with c-Fos/Dusp1 inhibitors and imatinib cured 90 percent of mice with CML, with no signs of residual disease cells.

Azam and his colleagues also point to an interesting finding involving solo treatment with just the deletion of c-Fos and Dusp1. This eliminated expression of the signaling proteins and was sufficient to block B-ALL development, eradicating the disease in mouse models.

Next steps

The authors stress that because the study was conducted in laboratory mouse models, additional research is needed before the therapeutic strategy can be tested in clinical trials.

They are following up the current study by testing c-Fos and Dusp1as treatment targets for different kinase-fueled cancers, including certain types of lung cancer, breast cancers and acute forms of leukemia.

Explore further: Technique identifies chemotherapy-resistant cells within acute myeloid leukemia tumors

More information: Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia, Nature Medicine, nature.com/articles/doi:10.1038/nm.4310

Although chemotherapy can sometimes cure acute myeloid leukemia and other hematologic cancers, many patients experience relapses when their tumors become resistant to available chemotherapies. This resistance may be caused ...

Acute myeloid leukemia (AML) is a cancer of myeloid stem cells that develops in both adult and pediatric populations. Mutations that cause hyperactivation of the FMS-like tyrosine kinase 3 (FLT3) are commonly found in AML, ...

A study in mice combining two inhibitor drugs for treatment of chronic myeloid leukemia (CML) has revealed potential for not only stopping the disease completely, but also significantly lowering the cost for treatment. CML ...

New research takes aim at stubborn cancer stem cells that are thought to be responsible for treatment resistance and relapse. The study, published by Cell Press in the February 14 issue of the journal Cancer Cell, provides ...

August 29, 2013) St. Jude Children's Research Hospital scientists have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to fashion a more effective ...

Genetic mutations that cause cancer also weaken cancer cells, creating an opportunity for researchers to develop drugs that will selectively kill them, while sparing normal cells. This concept is called "synthetic lethality" ...

Scientists identify two signaling proteins in cancer cells that make them resistant to chemotherapy, and show that blocking the proteins along with chemotherapy eliminate human leukemia in mouse models.

Combining single-cell genomics and computational techniques, a research team including Paul Robson, Ph.D., director of single-cell biology at The Jackson Laboratory (JAX), has defined cell-type composition of cancerous cells ...

Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond ...

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School ...

New King's College London research sheds light on the cellular mechanisms which enable cancer cells to escape the prostate and spread to other parts of the body.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original post:
Scientists find possible Achilles heel of treatment-resistant cancers - Medical Xpress

AkzoNobel’s Imagine Chemistry Challenge Generates More Than 200 Ideas – BodyShop Business

AkzoNobel announced that an enthusiastic response to its Imagine Chemistry initiative has resulted in more than 200 innovative ideas being submitted by chemistry start-ups, scientists, research groups and students around the world.

Developed in conjunction with KPMG, Imagine Chemistry was launched to help solve real-life chemistry-related challenges, such as finding ways to revolutionize plastics recycling, as well as uncovering sustainable opportunities for AkzoNobels Specialty Chemicals businesses.

From the 200 submissions received, AkzoNobel will now select 20 finalists to attend a three-day event in June at the companys principal research facility in Deventer, the Netherlands.

We have been very impressed by the number and quality of the submissions, said Thierry Vanlancker, AkzoNobels Executive Committee member responsible for Specialty Chemicals. This confirms our belief that there is tremendous potential even in mature chemistries. We are looking forward to working with the eventual winners to scale up their ideas and turn them into a commercial reality with real global impact.

The Imagine Chemistry challenge is focused on finding solutions in five areas:

There are also open challenges for broad ideas in two further areas: highly reactive chemistry and technology, and sustainable alternatives to current technologies.

The challenge is part of an integrated approach to further deploy AkzoNobels innovation capability in support of its growth ambitions.

We put innovation and sustainability at the heart of everything we do, saidVanlancker. Our strategic ambition is to deliver a world-beating product portfolio across all our markets, building on collaborative and open innovation.

Recent innovations from AkzoNobels Specialty Chemicals business include Bolikel XP, a next generation, biodegradable micronutrient to efficiently combat iron deficiency in crops; and Berol DR-B1, a safe and sustainable surfactant for consumer and commercial cleaning applications that involve direct release.

See the article here:
AkzoNobel's Imagine Chemistry Challenge Generates More Than 200 Ideas - BodyShop Business

New database highlights cumulative chemical dangers – Chemistry World (subscription)

A collaborative and publicly available database of previously inaccessible hazardous chemical reactions has been launched by the Pistoia Alliance, a not for profit group based in Boston, US.

This new Chemical Safety Library (CSL) service features a submission tool that allows researchers to add safety data in just minutes, helping to prevent dangerous events from being repeated. The system was designed in conjunction with Pistoias industry members, including Bristol-Myers Squibb, AstraZeneca and Pfizer.

Although many commercial and open resources already offer information on the hazardous properties of individual reagents, often there are no details about the effect of combining such reagents, according to Steve Arlington, the Pistoia Alliances president. In addition, such events are often not shared within or between companies.

The CSLs chemical reaction incident dataset can be downloaded, and it can also be configured to alert scientists if there is a known safety risk before they carry out a research project.

Within hours of Pistoia announcing the CSL on 16 March, 150 people had already signed up to use the new system, says Carmen Nitsche, a business development consultant for Pistoia. Users have access to the base set of about 25 incidents with which Pistoia pre-populated the system, and they can enter their own incidents, which will then be reviewed before being approved. If we are successful, this will be a resource for academia, for chemical companies, for anyone who has lab scenarios where this could be useful, Nitsche tells Chemistry World.

Original post:
New database highlights cumulative chemical dangers - Chemistry World (subscription)

A&M brings chemistry road show, virtual reality to SXSW – Texas A&M The Battalion

Among the dozens of displays, interactive events and panels available to participants of South by Southwest last week, the Aggies stole the show with seven activations highlighting work from across the university.

South by Southwest is a globally recognized festival which draws together interactive, film and music industries, attracting tens of thousands each year. This year Texas A&M took over the Hotel Van Zandt, filling it with displays such as a chemistry road show, a virtual reality display combining art with technology and an Aggies Invent competition.

Amy B. Smith, senior vice president and chief marketing and communications officer at Texas A&M, said she felt A&Ms mission at South By Southwest was successful.

A definite yes on building awareness and enhancing reputation by showcasing student and faculty work in a very futuristic manner, Smith said. Time will tell on our third goal: To grow the number of Fortune 500 companies hiring our students. There were many companies present who saw our exhibits and feedback was tremendous.

Marco Palma, associate professor and extension economist with the Human Behavior Laboratory, and Steven Woltering, assistant professor and Director of the Neurobiological Lab for Learning and Development, were two of the members of a four-member group called The human lab: Revealing the emotional brain, which demonstrated how they connect brainwaves and track eye movement and facial expressions to determine a persons choices.

Woltering said each of the members of the panel emphasized the possible application of biometrics in different fields.

My presentation aimed to show how biometrics can revolutionize the field of education in the future, Woltering said. I wanted the audience to know about a new initiative at the College of Education called the Neurobiological lab for Learning and Development (NLD) which aims to bridge recent advances in neurobiology and apply them in an educational context.

Palma said he was excited to see the variety of events A&M at South by Southwest and enjoyed the experience of participating.

It was great to have the opportunity to share our vision for the Human Behavior Laboratory, Palma said. We hope to be able to engage with faculty and students interested in using this technology in their research and outreach efforts.

Smith said she hopes to eventually bring A&M back to South by Southwest.

It makes sense to go back, Smith said. The event is global but based nearby. It is attended by corporations who hire our students, media who can spread the word about what we do, venture capital investors and government agencies who provide grants.

Smith said A&Ms participation in South by Southwest is part of a bigger picture.

This is about telling the story of the amazing things that Texas A&M students and faculty do, Smith said. SXSW participation was just a small step. There is more to come born in the minds of scholars who may be reading this now and who will be featured next year.

Read the rest here:
A&M brings chemistry road show, virtual reality to SXSW - Texas A&M The Battalion

UCLA researchers make DNA detection portable, affordable using cellphones – UCLA Newsroom

Researchers at UCLA have developed an improved method to detect the presence of DNA biomarkers of disease that is compatible with use outside of a hospital or lab setting. The new technique leverages the sensors and optics of cellphones to read light produced by a new detector dye mixture that reports the presence of DNA molecules with a signal that is more than 10-times brighter.

Nucleic acids, such as DNA or RNA, are used in tests for infectious diseases, genetic disorders, cancer mutations that can be targeted by specific drugs, and fetal abnormality tests. The samples used in standard diagnostic tests typically contain only tiny amounts of a diseases related nucleic acids. To assist optical detection, clinicians amplify the number of nucleic acids making them easier to find with the fluorescent dyes.

Both the amplification and the optical detection steps have in the past required costly and bulky equipment, largely limiting their use to laboratories.

In a study published onlinein the journal ACS Nano, researchers from three UCLA entities the Henry Samueli School of Engineering and Applied Science, the California NanoSystems Institute, and the David Geffen School of Medicine showed how to take detection out of the lab and for a fraction of the cost.

The collaborative team of researchers included lead author Janay Kong, a UCLA Ph.D. student in bioengineering; Qingshan Wei, a post-doctoral researcher in electrical engineering; Aydogan Ozcan, Chancellors Professor of Electrical Engineering and Bioengineering; Dino Di Carlo, professor of bioengineering and mechanical and aerospace engineering; andOmai Garner, assistant professor of pathology and medicine at the David Geffen School of Medicine at UCLA.

The UCLA researchers focused on the challenges with low-cost optical detection. Small changes in light emitted from molecules that associate with DNA, called intercalator dyes, are used to identify DNA amplification, but these dyes are unstable and their changes are too dim for standard cellphone camera sensors.

But the team discovered an additive that stabilized the intercalator dyes and generated a large increase in fluorescent signal above the background light level, enabling the test to be integrated with inexpensive cellphone based detection methods. The combined novel dye/cellphone reader system achieved comparable results to equipment costing tens of thousands of dollars more.

To adapt a cellphone to detect the light produced from dyes associated with amplified DNA while those samples are in standard laboratory containers, such as well plates, the team developed a cost-effective, field-portable fiber optic bundle. The fibers in the bundle routed the signal from each well in the plate to a unique location of the camera sensor area. This handheld reader is able to provide comparable results to standard benchtop readers, but at a fraction of the cost, which the authors suggest is a promising sign that the reader could be applied to other fluorescence-based diagnostic tests.

Currently nucleic acid amplification tests have issues generating a stable and high signal, which often necessitates the use of calibration dyes and samples which can be limiting for point-of-care use, Di Carlo said. The unique dye combination overcomes these issues and is able to generate a thermally stable signal, with a much higher signal to noise ratio. The DNA amplification curves we see look beautiful without any of the normalization and calibration, which is usually performed, to get to the point that we start at.

Additionally, the authors emphasized that the dye combinations discovered should be able to be used universally to detect any nucleic acid amplification, allowing for their use in a multitude of other amplification approaches and tests.

The team demonstrated the approach using a process called loop-mediated isothermal amplification, or LAMP, with DNA from lambda phage as the target molecule, as a proof of concept, and now plan to adapt the assay to complex clinical samples and nucleic acids associated with pathogens such as influenza.

The newest demonstration is part of a suite of technologies aimed at democratizing disease diagnosis developed by the UCLA team. Including low-cost optical readout and diagnostics based on consumer-electronic devices,microfluidic-based automation andmolecular assays leveraging DNA nanotechnology.

This interdisciplinary work was supported through a team science grant from the National Science Foundation Emerging Frontiers in Research and Innovation program.

Go here to see the original:
UCLA researchers make DNA detection portable, affordable using cellphones - UCLA Newsroom

Anatomy Of A Decision, Part 1: The C-Suite – Yahoo Finance

Professional networking leader GLG has produced a new series of videos focused on decision making in the business world. As part of the series, GLG has interviewed a number of business leaders to ask about what considerations go into making important decisions.

In the first installment, GLG speaks with former Pfizer Inc. (NYSE: PFE) CEO Jeff Kindler.

Kindler said a key ingredient in his meteoric rise was an open mind.

The Importance Of An Open Mind

I started saying I should be open to whatever comes along, Kindler said. And that led me down all kinds of different paths I never would have predicted.

Kindler joined Pfizer as the pharma giants general council, but he admits that he had always had ambitions to be CEO. Once he assumed the role, he was presented with an opportunity to work with former President Barack Obama on the Affordable Care Act (ACA).

Kindler said many of the provisions being discussed at the time were politically polarizing but would have been universally bad for the pharmaceutical industry. Rather than fight the change, Kindler and a handful of other pharma CEOs decided to take a more constructive approach.

We formed a small group of five of us who were CEOs of different companies in pharmaceuticals with different interests and a different focus, and we decided that within the right boundaries, if we could achieve acceptable policy solutions, we would support the bill, Kindler recalled.

To this day, there are people who dont like what we did, even within the pharmaceutical industry. But my view is I got attacked by both the Wall Street Journal and the New York Times editorial page, and I think when that happens you know youre in the sweet spot.

Lessons Learned

Kindler sees his participation in the process as a valuable lesson in the power of compromise. While the pharmaceutical industry made a number of financial sacrifices as part of the process, he and his colleagues were also able help shape the bill to maximize potential industry benefits.

Kindler said the success of Obamacare to this day depends on perspective. In terms of increasing health insurance coverage, the program was a complete success. In terms of fixing the underlying problems of rising healthcare costs, Kindler believes Obamacare hasnt delivered.

He closed the interview by discussing one key regret he has about his time as CEO.

I think I fell prey to something thats in human nature, which is I didnt block enough time for personal development. I think a lot of [people] that are Type A personalities end up in big jobs, and theyre so focused on both the fact that they have achieved that and the things that they need to do on it that they... just dont pay attention enough to the things that are of long-term importance.

Kindler said time management, prioritization and mentorship were three of the biggest challenges of such an important professional role.

Related Link:

6 Outsider CEO Hires That Flopped

See more from Benzinga

2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Continued here:
Anatomy Of A Decision, Part 1: The C-Suite - Yahoo Finance

Genetic Engineering Can Help Us Save Animals’ Lives – malaysiandigest.com

Details Published on Monday, 20 March 2017 13:31

Manipulating Genetics With or Without CRISPR

From tackling cancer to eradicating single-gene mutations, the CRISPR/Cas9 gene editing tool is often portrayed as the eighth wonder of the world by many. We look to CRISPR regarding how it affects us as a species, but the implications of the CRISPR Cas-9 system extend far beyond just humanity. The gene editing tools precision and efficacy can be implemented in manipulating the genetics of our agriculture as well as animals. It would be wrong, however, to think that this is humanitys first attempt at the genetic manipulation of crops and pets aliketo be fair, we have been doing it since the inception of human civilization itself.

Thirty thousand years ago, our ancestors were the first individuals to manufacture genetically modified organisms (GMOs) before it was cool. Through selective breeding or artificial selection, wild wolves in East Asia were selected for docility. With more obedient animals at their side, humans from 32,000 BCE could optimize their hunter/gatherer lifestyles. After several millennia, the artificially-selected wolves began to resemble the dogs we see today. Crops werent spared from our genetic coercion either. In fact, humans had domesticated several forms of wheat since 7800 BCE. However, our greatest success in genetic modification through artificial selection comes from corn. Corns is derived from a wild grass known as teosinte, which only occurred when humans at the time selectively planted corn kernels that displayed desirable traits. Over time, this behavior reconciled the five-gene difference between corn and teosinte and led to the desirable crop that we use to this day.

Its clear that humanitys days of artificial selection arent behind us, as most major crops today are genetically engineered for our benefit. Rather than waiting around a few thousand years for evolution to do its work, we are now able to immediately manipulate the genetic information of organisms; an idea first executed in 1973 by Stanley Cohen, Herbert Boyer, Annie Chang, and Robert Helling to provide anti-bacterial resistance to a certain strain of bacteria. Since then, gene editing has exploded in all directions. Thanks to genetic engineering, we now dehorn cattle, produce disease-resistant pigs, and herd goats that grow longer hair, all in the name of productivity.

CRISPR and Animal Regulation: Do We Need It?

So how does CRISPR work? Unlike other gene editing tools in the past, CRISPR works to propagate sequences through generations at a 97% effectiveness rate. The system is naturally found in viruses, but researchers were able to manipulate the tool to essentially work as a copy and paste function for any desirable genetic information. The advent of CRISPR is revolutionizing business, with corporations taking advantage of the easy-to-use genetic engineering to even edit pets to sell. However, while CRISPR does essentially accelerate mankinds ability to artificially select traits for organisms that we find beneficial, people like David Ishee, a Mississippi kennel operator, believe that we can reverse the negative side effects of artificial selectionparticularly hyperuricemia (an abnormally high level of uric acid in the blood) in Dalmatians. While David feels that its a relatively simple request to utilize gene editing in the hopes of ameliorating a human-caused condition in the breed of dogs, the U.S. Food and Drug Administration (FDA) feels differently.

Ishee, and many others like him who wish to genetically modify animals, face the FDAs newly drafted regulations from January 2017. While Ishees plan to modify the malfunctioning genes of Dalmatians and re-insert them into healthy sperm before fertilization isnt outlawed by the FDA, its distribution is.

If Ishee manages to produce healthy Dalmatians without the disease, he would not be able to sell or distribute them for breeding purposes, according to the FDA. With that said, Ishees hope of spreading his movement far and wide might just be curtailed by government regulation.

The new measures by the FDA might just be a response to the emerging fear that CRISPR and other gene editing techniques can be utilized as weapons of mass destruction. While there are those who dont intend on adhering to the regulations, hoping the new administration would absolve them entirely, there are others like Ishee who are stonewalled against even starting their projects. However, the benefits of being able to use CRISPR on animals DNA could be huge; just looking at dogs and cats alone, selective breeding has introduced some unfortunate side effects. We could help our pets live longer, more comfortable lives in the future. Dalmatians shouldnt have to suffer because humans wanted a dog that had spots, and perhaps we can undo some of the damage weve done in the name of purebred dogs and cats. Scientists and others who want to use this technology also argue that doing this is completely different than splicing two animals DNA together, for example.

-Futurism

See original here:
Genetic Engineering Can Help Us Save Animals' Lives - malaysiandigest.com

Highly Respected Anti-Aging Specialist, Garry Fredric Gordon, MD, DO, MD(H), will be Spotlighted in The Leading … – PR NewsChannel (press release)

The International Association of HealthCare Professionals is pleased to welcome Garry Fredric Gordon, MD, DO, MD(H), Anti Aging Specialist to their prestigious organization with his upcoming publication in The Leading Physicians of the World. Dr. Garry Fredric Gordon is a highly trained and qualified physician with an extensive expertise in all facets of his work, especially naturopathic medicine. Dr. Gordon has been in practice for more than five decades and is currently working within his own private practice, the Gordon Research Institute in Payson, Arizona.

Dr. Garry Fredric Gordon graduated with his Medical Degree in 1958 from the Chicago College of Osteopathic Medicine in Downers Grove, Illinois. He later gained an additional Medical Degree from the University of California at Irvine, and completed a residency at the UCSF Medical Center at Mount Zion.

Dr. Gordon is a world renowned expert on detoxification and on chelation therapy. He serves as an advisor to the American Board of Chelation Therapy, and is President of the Arizona Homeopathic and Integrative Medical Association. To keep up to date with the latest advances in his field, Dr. Gordon maintains a professional membership with the American College for Advancement in Medicine. He attributes his success to his love for the field, and when he is not working, Dr. Gordon enjoys bike riding.

Learn more about Dr. Gordon here: http://gordonresearch.com/ and be sure to read his upcoming publication in The Leading Physicians of the World.

About FindaTopDoc.com

FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics. Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review. FindaTopDoc.com features each doctors full professional biography highlighting their achievements, experience, patient reviews and areas of expertise. A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life. For more information about FindaTopDoc, visit http://www.findatopdoc.com

Link:
Highly Respected Anti-Aging Specialist, Garry Fredric Gordon, MD, DO, MD(H), will be Spotlighted in The Leading ... - PR NewsChannel (press release)

Boys Player of the Year: It’s all about team chemistry for Panthers’ standout – Northeast Mississippi Daily Journal

Sports Boys Player of the Year: Its all about team chemistry for Panthers standout

Thomas Wells | Buy at photos.djournal.com Amory senior striker Brendan Koehn scored 22 goals with seven assists as the Panthers went 20-2-1 and reached the state semifinals for a second year in a row.

By Melissa Meador

Monroe Journal

Amory forward Brendan Koehn didnt let starting the soccer season a few games late slow him down.

The senior, who was a kicker for the football team, still scored 22 goals and notched seven assists as he helped lead the Panthers to their second-straight North finals appearance.

Missing the first few games was awful. It killed me, but I knew I couldnt just leave football. That season came first, Koehn said. I played in a few tournaments during the football break, so I felt like I was still in my groove with soccer.

Koehns play this season led to him being named the Daily Journals Player of the Year.

Koehn attributes the Panthers success over the last few years to team chemistry, some of which was fostered while working as teammates on Amory youth teams.

We together growing up. Our freshmen year, when we lost 7 or 8 seniors, it was our time to step up, said Koehn, who scored 31 goals as a junior. Last year, we had the season of a lifetime, and we took everyone by surprise. I felt like this year was our year. We made it to North half again, but I think we came in with a sense of pride that we were already going through, and we didnt play our game.

He and teammates Aaron Pressley, Jake Kirkpatrick, Ryan Morgan and Austin Rowell will carry that chemistry to ICC, as all five signed with the Indians.

Excited for future

Its incredible, seeing where we started and where we are now. Next year could be unbelievable, Koehn said. Its not only us five, but its teammates that Ive had over the past few years, too. We all have chemistry in some form.

Koehn was recently named the MVP of the Mississippi Association of Coaches All-Star soccer game in Clinton after scoring a hat trick in the Norths win.

I was ecstatic, because I wanted to be one of those guys who went down there and performed, he said. It was a group of guys with unbelievable skill and talent down there. It was probably my most memorable moment of the high school season.

melissa.meador@journalinc.com

Twitter: @MelissaMeador14

Follow this link:
Boys Player of the Year: It's all about team chemistry for Panthers' standout - Northeast Mississippi Daily Journal

Diverse personalities, unique chemistry helped 2009-10 Jackson boys basketball make history – Canton Repository

STARK'S GREATEST TEAMS: Polar Bears earned first team state title in school history, peaking with dominant performances in Columbus

JACKSON TWP. What a strange brew it was, this blue-collar team from the white-collar town.

There was the easy-going center, the pit-bull point guard and the mohawk-wearing forward.

The young coach, a self-described pessimistic Italian, tried to find his teams summer magic during the cold winter months of late 2009 and early 2010. Just when he had almost given up, it appeared again, leaving the opposition dazed and Ohio basketballs biggest stage shrouded in a purple haze.

The story of the 2009-10 Jackson High School boys basketball team was one of timing, unique chemistry and history made. The Polar Bears went 25-2 and won the schools first team state championship in any sport.

Seven years later, the main characters (now in their mid-20s) still revel in the memories.

I get goose bumps, center Mark Henniger said.

You get chills thinking about the moment, point guard Brad DuPont said.

Blissful, forward Josh Egner described. Its still almost like a dream.

Dreams of Columbus didnt necessarily occupy much of their thoughts entering that season.

This wasnt an all-star team of transfers and move-ins. Jackson isnt an open-enrollment school. The Polar Bears were homegrown. They were Jackson kids.

Outside of Canton city, Stark County hadnt produced a boys basketball state title since 1939.

And, really, how can a team expect to win a state title when it cant even beat its local rival? The year before, Jackson went 17-5, with three of the losses coming at the hands of Hoover, which won the Federal League and the district.

Mike Fuline, then 34, was in his fifth of six years as Jacksons head coach in 2009-10. The Polar Bears, with the senior nucleus of Henniger, Egner and DuPont, had steadily progressed through his tenure. But labeling Jackson a state title contender seemed like a stretch.

We never thought about winning a state championship because we hadnt even won the Federal League, said Fuline, now the University of Mount Union mens basketball coach. As good as that team was, we hadnt won anything.

So the Polar Bears started winning things.

The league. The brutal Canton Division I district tournament. They beat Hoover three times to exorcise some demons.

Before they knew it, they were in Columbus.

If the moment was too big for them, they didnt show it.

The morning of the state semifinal game, Fuline walked by the indoor pool at the team hotel.

Six of our guys are in there playing chicken, Fuline said. Henniger has C.J. (Julian) on his shoulders. Theyre fist fighting. You know how youre not supposed to swim the day of a game? Well, its a full-out brawl in there. I looked in and just kept walking. They were the weirdest dudes I ever met.

Julian, who was the teams defensive specialist and main agitator, put it this way: We were just a wacky team. Wed do some of the dumbest things in the locker room.

But when the lights came on, we competed.

Henniger and Julian would yawn during pregame intros, then give maximum effort once the ball was tipped.

For years, opposing fans have taunted Jackson athletes as, basically, soft rich kids who wear purple. But these Polar Bears were not entitled, and they certainly werent soft. Egner snarled when he dunked. DuPont played with an angry intensity that intimidated opponents.

Fuline believes the character of his players started with their parents.

Nothing was ever given to them at home, he said. There was accountability at home and there was a toughness about them that I can only hope that my son, growing up in Jackson, will have.

The 6-foot-6 Egner, who averaged 13.2 points and 7.9 rebounds, brought a big-play flair to Jackson with his dunks, blocks and mohawk before playing two years in college at Akron.

The 6-foot DuPont, who was built like a running back, was Jacksons engine and vocal leader. He averaged 9.7 points, 2.7 steals and a county-best 6.8 assists before going on to play at Wheeling Jesuit and Walsh University.

And then there was the 6-8 Henniger, the calm in the storm. With a steady game and a steady personality, Henniger averaged 20.9 points, 8.9 rebounds and 2.7 blocked shots while shooting 62.3 percent from the floor. He was the Canton Repository Stark County Player of the Year and a first-team All-Ohioan. His 1,552 career points rank seventh in county history and second in Jackson history.

He was so good you took him for granted, Fuline said of Henniger, who went on to play collegiately at Kent State and professionally one season in Malta.

The rest of Jacksons starting lineup was Julian and the lone junior, Michael Shull, who provided floor spacing by averaging 9.9 points and shooting 40.5 percent from the 3-point line.

Senior David Devine was another good defender off the bench, while senior Nathan Kanam and juniors James Feller and Tyler Graening also provided minutes.

I think sometimes people saw 13 long, skinny white kids coming out and thought, These Jackson kids, well get out and outrun them, Egner said. About a quarter and a half in, they'd realize they made a huge mistake.

Jackson outscored the opposition 69.5 to 51.2 on average that season.

The Polar Bears provided a glimpse of their potential in June 2009. Their summer schedule, which took them from Wheeling, W.Va. to Ann Arbor, Mich., produced a 36-2 record against tough competition.

In the regular season, Jackson also lost just twice against Mentor 70-67 in San Diego in December and against Huber Heights Wayne 62-53 in Columbus the day after a Jan. 22 overtime win against Hoover. Still, Fuline felt like something was missing. The Polar Bears werent playing at their highest level.

That summer, leading up to it, we were unbelievable, Fuline said. What you saw in Columbus (during the state tournament), thats what we were in the summer. So youre excited. Then the season starts and you dont see that for literally 20 games.

Jackson beat Hoover 63-44 in the Federal League tournament championship game, completing a 10-0 league run.

After walloping Massillon in a sectional final, the Polar Bears tournament run became very interesting.

They were down 12 points to 10th-seed Lake at the half in a district semifinal but rallied to win 56-49.

That set up Round 3 with Hoover, this time for the district title. Jackson led 55-52 with 10.5 seconds left.

I look at them and ask if they want to foul, Fuline said. And Egner yells, We aint fouling. Guard them!

That Egner did, blocking a 3-point attempt by Hoovers Cory Veldhuizen in the final seconds to basically seal Jacksons first district title in nine years.

The Polar Bears survived quite a scare against Akron East in the regional semifinal at Akrons Rhodes Arena. In a game with 15 lead changes, Jackson hung on for a 58-56 win only after East missed twice in the final seconds.

Another two-point game awaited in the regional final. Jackson earned a trip to state with a 52-50 win over Toledo St. Johns and a freshman by the name of Marc Loving, who would become a Parade All-American and four-year player at Ohio State.

The Polar Bears celebrated. But deep down, the specter of facing Columbus Northland loomed in the state semifinal. With future NBA players Jared Sullinger and Trey Burke, Northland the defending state champion was ranked No. 1 in the country and undefeated.

I remember Bygz (late Jackson basketball manager Mike Bessler) coming up to me, Fuline said. Were still on the floor (at Akron). He says, Mikey, Gahanna beat them.

Your mindset goes from happy to Lets go to work.

Word of Gahanna Lincolns shocking 71-45 upset of Northland in a regional final spread quickly through Jacksons team.

We kind of looked around and said, 'Were going to win states
,' Henniger said. That was really the first time we sat down and thought, Were going to do this.

Keep in mind, Gahanna was undefeated and featured three future Division I college guards Rob Brandenberg (VCU), Anthony Jackson (Stony Brook) and Stevie Taylor (Ohio).

But Jacksons confidence was at an all-time high.

And it proved valid when the Polar Bears beat Gahanna 62-50.

Egner had maybe his best game of the season, totaling 23 points, 11 rebounds and four blocked shots.His big night included an off-the-backboard alley-oop from DuPont in the third quarter that had Jackson fans going wild.

It was pretty awesome and something Ill always remember. Im sure Josh will, too, DuPont said. Those things, when they happen, are totally not planned. You just know who your teammates are and what they are capable of.

The state final was the next night and Jackson faced Cincinnati Moeller, which had beaten Mentor in overtime in the semifinal.

Before the final, Egner asked Fuline if the team could change into their uniforms at the hotel. So the Polar Bears wore their their game gear and carried their sneakers as they rolled up to Value City Arena in vans (I dont know why I made that decision to have vans instead of a bus to this day, Fuline said).

Meanwhile, Moeller was arriving at the same time, in a charter bus, with the players wearing suits and ties.

Egner says, Look at these (expletives),'" Fuline said. I laughed and thought, Were going to kill these dudes.

Fuline liked the matchup with Moeller, and his instinct was correct. With 12,920 fans in the stands, the Polar Bears dominated the Crusaders 57-34, highlighted by a 16-0 run to begin the third quarter.Henniger had 21 points and 12 rebounds. Shull scored 17 points, while DuPont added 11 points and five assists.

After winning their four previous tourney games by a combined 14 points, Jackson won its two state games by a combined 35. It was the biggest margin by a Division I state champion since McKinley crushed Toledo St. Johns and Trotwood-Madison by a combined 48 in 2006.

Finally, Fuline saw the boys of summer.

It was refreshing because I wanted everybody to see how good they were, he said.

Jackson finished the season 22nd in USA Todays national rankings.

It didnt make sense how the pieces fit together so perfectly. But years of spending just as much time with each other on the court as off forged a group that cared for each other and sacrificed for each other.

These Jackson kids just wanted to win something.

They ended up winning the ultimate prize.

What you saw on the court was real, DuPont said. These guys are my friends that I hang out with. It just makes you proud of what we did, what we did for our community.

Reach Josh at 330-580-8426or

josh.weir@cantonrep.com

On Twitter: @jweirREP

Go here to read the rest:
Diverse personalities, unique chemistry helped 2009-10 Jackson boys basketball make history - Canton Repository

Maria Feeney, Tara Sander Lee and Kathleen M Schmainda: Fetal tissue from abortions is (still) not needed for … – Madison.com

Two bills have recently been introduced in the Wisconsin Legislature to provide a path forward for biomedical research that honors the dignity of the human beings that it is meant to serve. These are the Fetal Remains Respect Act and the Unborn Child Disposition and Anatomical Gift Act, part of the Heal Without Harm Legislative Initiative. Contrary to what some claim, these bills do not stifle research. As scientists, we wholeheartedly support this initiative to support and advocate for biomedical research that benefits all human persons, without sacrificing one for another.

These bills come on the heels of a yearlong investigation of the abortion industry by the U.S. House Select Investigative Panel. The final report corrects many false and misleading statements regarding the role of fetal tissue in science and medicine. In nearly 100 years of unrestricted research, the panel investigation confirms, not a single clinical treatment has been developed from human fetal tissue. Vaccines for polio, measles, and mumps were never produced using human fetal tissue but rather used monkey cells, chicken eggs, and nonfetal human cells. None of the 75 vaccines available in the U.S. is produced using fresh fetal tissue. The continued use of certain cell lines derived from aborted fetal tissue to produce a small portion of vaccines (less than 15 percent) is due more to the high cost of switching than to any scientific reason. In regard to development of new vaccines, greater than 98 percent of research articles published on Zika do not use fetal tissue. Conversely, adult blood cells recently led to a breakthrough in vaccine development for Cytomegalovirus (CMV), a virus affecting brain development in a way similar to Zika.

The panel investigation further discredits the claim that fetal tissue plays an indispensable role in life-saving research. Fetal tissues (or byproduct stem cells) are used in only 0.01 percent of clinical trials currently underway and in merely 0.2 percent of grants funded by NIH between 2010-2014 none of which is investigating Alzheimers disease, where many claim fetal tissue is required and the gold standard. In many cases, aborted fetuses are not the most appropriate tissue source, but these tissues are still used because they are cheaper and easier to obtain than adult tissues. These facts suggest that, in practice, even scientists are not convinced that fetal tissue is critical to research.

In stark contrast, people suffering with cancer, diabetes, heart disease, neurological diseases, and others are benefiting now from clinical trials and treatments using adult stem cell therapies. Adult stem cells have saved the lives of over 1 million people worldwide, but not one person is alive today because of stem cells from aborted fetal tissue.

Therefore, as a next step, the panel provides several recommendations to ensure the advancement of research that is superior both scientifically and ethically, followed by a call for increased federal investment in these areas. Wisconsin risks losing time, money and lives if an ethical approach to research is not advocated and supported. It is within Wisconsins best interest to pass these bills. Science and ethics do work together.

Maria Feeney, of West Bend, has a Ph.D. in pharmaceutical chemistry and conducts research in biochemistry. Tara Sander Lee, of Brookfield, has a Ph.D. in biochemistry and researches molecular and cellular biology. Kathleen M. Schmainda, of Elm Grove, has a Ph.D. in biochemistry and conducts brain cancer research.

Share your opinion on this topic by sending a letter to the editor to tctvoice@madison.com. Include your full name, hometown and phone number. Your name and town will be published. The phone number is for verification purposes only. Please keep your letter to 250 words or less.

Read the original post:
Maria Feeney, Tara Sander Lee and Kathleen M Schmainda: Fetal tissue from abortions is (still) not needed for ... - Madison.com